31 results about "Stage tumor" patented technology

The invention discloses a colorectal early-stage tumor data analysis early-warning method based on reinforcement learning, and the method comprises the steps: achieving the semantic alignment and weighted fusion through the unified expression of different modal features, and employing a differentiable attention unit; dynamic strategy optimization is carried out in combination with a reinforcement learning model, and the generalization ability and early warning accuracy of heterogeneous data are improved; a dynamic weight adjustment and online learning mechanism is introduced, continuous self-adaptive updating of the model and compensation of a data missing scene are realized, the accuracy and stability of colorectal tumor risk early warning are improved, and the method has high clinical application and popularization value.

The invention discloses a method for accurately identifying benign and malignant cells based on multi-dimensional characteristics of a single cell transcriptome, and belongs to the technical fields of bioinformatics, tumor molecular biology and cell identification. On the basis of single cell transcriptome sequencing data of tumor tissues and para-carcinoma tissues, three types of information including copy number variation, allele specific copy number variation and tumor-related transcriptional characteristics are synthesized, and final benign and malignant identification is performed on each EpCAM positive epithelial cell through a multi-evidence voting strategy. The method disclosed by the invention has relatively high stability and accuracy in a multi-patient, multi-sample and early tumor scene, particularly improves the recognition capability of early lesion and malignant cells in benign and malignant boundary transition state cells, and provides a reliable technical means for precise diagnosis and individualized treatment of tumors.

This disclosure relates to a method for detecting colorectal cancer. The method comprises determining whether an advanced neoplasm is present in a first screening time period and upon determining that an advanced neoplasm is present in the first screening time period, performing colonoscopy in a second screening time period, after the first screening time period, to detect colorectal cancer. There is further provided a method for stratification of a subject comprising upon detection of an advanced neoplasm in a first screening time period, stratifying the subject into a high risk stratification for developing colorectal cancer in a second screening time period. There is further provided a computer implemented method for calculating a risk score for developing colorectal cancer comprising determining patient data; applying a trained machine learning model to the patient data to determine the risk score; and outputting the risk score.

The application provides a kind of nanoparticle, preparation method and its early screening related application of cancer, wherein, nanoparticle includes superparamagnetic nanometer core, cationic polymer modified on the surface of superparamagnetic nanometer core and targeted polypeptide grafted on cationic polymer, the targeted polypeptide can specifically recognize tumor specific antigen protein, and has the modular structure of rigid helix and charge repulsion sequence.The plasma low-abundance protein enrichment nanoparticle provided by the application can be used for the detection of early screening of tumor through liquid biopsy, can significantly improve the detection rate of early tumor, and has important clinical significance.

The invention provides a nanoparticle, a preparation method and a cancer early screening related application thereof, the nanoparticle comprises a superparamagnetic nano core, a cationic polymer modified on the surface of the superparamagnetic nano core and a targeting polypeptide grafted on the cationic polymer, the targeting polypeptide can specifically recognize a tumor specific antigen protein, and has a modular structure comprising a rigid helix and a charge repulsion sequence. The plasma low-abundance protein-enriched nanoparticles provided by the invention can be used for early screening detection of tumors through liquid biopsy, can significantly improve the detection rate of early tumors, and have important clinical significance.

The invention relates to the technical field of small-molecule contrast agents, in particular to a small-molecule contrast agent and a preparation method thereof. According to the micromolecule contrast agent provided by the invention, a divalent glycosyl group is introduced into a binary triiodo-benzene ring structure, so that each molecule contains six iodine atoms (the theoretical iodine content reaches 48.7 wt%), the molecular weight is controlled to be 2000Da or below, the water solubility is remarkably improved, the viscosity is reduced, and the performance is superior to that of a traditional contrast agent. Preliminary CT imaging experiments show that under the same molar concentration, the average CT value generated by the contrast agent YJY-86-2 is obviously higher than that generated by iohexol, and the contrast agent shows stronger imaging contrast ability. The characteristic is expected to realize better image quality while reducing the dosage of administration and reducing the risk of iodine exposure, and provides a powerful candidate material for realizing high-sensitivity detection of early tumors.

The invention discloses application of combination of carboxamidotriazole and revatinib in preparation of liver cancer drugs, a pharmaceutical composition and a preparation of the carboxamidotriazole and the revatinib, the drug combination of carboxamidotriazole and revatinib is used for the first time, the carboxamidotriazole and the revatinib show a remarkable synergistic effect, and in clinical medication, for patients with low sensitivity of using revatinib, the drug combination of carboxamidotriazole and revatinib has a remarkable curative effect on liver cancer. Through combination with carboxamidotriazole, the sensitivity of a patient to the medicine can be improved, and a synergistic effect is achieved. Meanwhile, as a non-cytotoxic drug, the carboxamide triazole can regulate the tumor inflammatory microenvironment, so that the tumor growth environment is changed, and the possibility of later development and metastasis of tumors is reduced. Meanwhile, the combination of carboxamidotriazole and lenvatinib has high safety, and provides more medication options for first-line patients.

The invention relates to the technical field of medical treatment, and discloses a transfer learning method for bad outcome prediction of small-sample early-stage cancer patients. According to the method, the neural network risk function is introduced and the transfer learning framework is combined, so that the nonlinear interaction of high-dimensional features can be better fitted, and the prediction accuracy of the small-probability bad outcome of the early-stage tumor is improved. Although the existing RSF can overcome linear hypothesis to a certain extent, the existing RSF is susceptible to noise interference in a small sample queue, and the prediction stability is insufficient. According to the migration survival forest method provided by the invention, by training and migrating structure priori on a large-scale database, a stable tree structure can be kept under a small sample condition, and a split threshold is re-estimated in combination with target data, so that global structure knowledge and local adaptability are taken into consideration, and the reliability of the system is improved. Therefore, the robustness and generalization ability of the model are remarkably improved.

This invention discloses an RNA-reactive fluorescent probe, its preparation method, and its application in tumor imaging and treatment. Upon response to ALP enzyme, the probe exhibits enhanced fluorescence, with a corresponding increase in photoacoustic intensity at 685 nm. Simultaneously, after enzyme response, the probe reacts with cytoplasmic RNA under red light irradiation, prolonging its residence time in tumor cells and achieving long-window tumor imaging. More importantly, this cross-linking reaction causes mitochondrial damage, leading to severe tumor cell apoptosis and thus inhibiting tumor growth. This invention's probe not only enables long-window near-infrared and photoacoustic dual-modal imaging of tumors but, more importantly, inhibits tumor growth, achieving integrated tumor diagnosis and treatment.

The invention belongs to the technical field of gene editing, and particularly relates to a construction method of a transgenic mouse with a tissue-specific precancerous marker. A fertilized ovum is constructed through a gene editing technology, a mutant p53 protein and a fluorescent protein are fused, a loxp-Stop-loxp sequence is added in front of a promoter of a mutant p53 sequence, the fertilized ovum is transplanted into a female mouse, the obtained progeny is an LPL transgenic mouse, and expression inhibition of the mutant p53 protein and the fluorescent protein is achieved; the LPL transgenic mouse is mated with a Cre tool mouse to obtain a transgenic mouse of which the offspring is a tissue-specific precancerous marker, the transgenic mouse expresses mutant p53 protein and fluorescent protein at a specific tissue, early tumor focus development is monitored and traced through a living body fluorescence imaging system, and the LPL transgenic mouse has extremely high application and research values.

The invention discloses a digestive tract tumor early screening system based on multi-omics data fusion, and relates to the technical field of tumor screening, the system comprises a double sample collection module, a synchronous detection module, a database support module, a fusion analysis module and a visual output module; according to the method, the accuracy and comprehensiveness of early screening of digestive tract tumors are improved through multi-omics data fusion, multi-dimensional data of fecal microbial genome DNA, metabolites, blood ctDNA and protein markers are integrated, biological information of four levels of florae, metabolism, genes and proteins is covered, and the accuracy and comprehensiveness of early screening of digestive tract tumors are improved through a three-level cross validation mechanism. According to the method, flora-metabolite synergy abnormality and gene-protein synergy abnormality can be recognized, the tumor risk value is calculated and the risk level is set in combination with positive threshold values and clinical weights in a multi-omics feature database, the detection rate of early tumors is increased, and the method has higher sensitivity especially for early digestive tract tumors without obvious symptoms.

This invention discloses a feline serum albumin-bound nanobody, its preparation method, and its applications, relating to the field of nanobody engineering technology. The amino acid sequence of the feline serum albumin-bound nanobody Nb1 is shown in SEQ.ID NO.1. The nanobody Nb1 not only exhibits high affinity for feline serum albumin but also good binding activity to mouse serum albumin, and can be widely applied in enhancing drug half-life during pet treatment, tumor targeted therapy and imaging, immune detection or diagnosis, and recombinant albumin purification or enrichment.

The invention discloses an anti-CD33 nano antibody as well as a preparation method and application thereof, and belongs to the technical field of nano antibodies. The invention provides a nano antibody for resisting a CD33 target spot, and the nano antibody has an antibody-dependent cell-mediated cytotoxic effect. The nano antibody has high affinity with both CD33 full-length protein and CD33 membrane-proximal terminal protein, obviously reduces immune risks caused by heterology, is more beneficial to penetrating a blood-brain barrier, can be used as an antigen binding domain for designing CAR, is easier to reach the interior of a tumor to play a therapeutic effect, and has a wide application prospect in preparation of drugs for preventing and / or treating advanced tumors.

The invention discloses a quantum sensing method for cross-class combined detection of tumor markers, which utilizes the quantum optical characteristics of an NV color center in a fluorescent nano-diamond as sensing signals to realize cross-class combined detection of two mainstream markers (miRNA and protein) in diagnosis of tumor diseases. The surface of the nano-diamond is functionally modified, and the charge state proportion situation of the NV color center is presented in a spectrum shape, so that the miRNA is detected. By constructing the magnetized gel, the detection of protein markers can be realized by utilizing an optical detection magnetic resonance (ODMR) signal of an NV color center. According to the method, on the basis that NV color center quantum has multiple optical signal characteristics, sensitive detection of miRNA-155 and MUC1 proteins is realized. The two sensing signals of the method are unisource and heterogeneous, so that the two sensing signals do not interfere with each other, and the method is suitable for sensitive and accurate detection of early tumor disease markers.

This invention belongs to the field of biodetection and medical technology, and relates to a high-performance photothermal diagnostic and therapeutic integrated fiber optic probe based on rare-earth nanomaterials. The probe includes a photothermal diagnostic and therapeutic composite material. This material consists of a tumor-specific environmental fluorescence responsive material, 1,8-naphthalimide fluorophore, and Yb that can be used for photothermal therapy. 3+ / Er 3+ The probe is composed of co-doped Bi₂WO₆ nanomaterials. Under 450nm laser excitation, the fluorescently responsive material in the probe emits 550nm green fluorescence in a tumor cell environment, which is received and fed back by the fiber optic probe, enabling specific recognition of tumor cells. After recognition, the fiber optic probe emits fluorescence that can be detected by Yb 3+ / Er 3+ The co-doped Bi₂WO₆ nanomaterials absorb and convert infrared light in the 980nm near-infrared band into photothermal radiation. Under continuous irradiation, the nanomaterials continuously heat up, destroying cell structures and killing tumor cells, thus achieving targeted photothermal monitoring and treatment of tumor cells. This probe is minimally invasive and has high photothermal conversion efficiency, providing a new approach for minimally invasive diagnosis and treatment of early-stage tumors.

PI3Kδ implicates hematologic cancers and solid tumors. Alternative splicing is a post-transcriptional process for acquiring proteomic diversity in eukaryotic cells. Emerging evidence highlights the involvement of aberrant mRNA splicing in cancer development / progression. PI3Kδ-L and PI3Kδ-S are overexpressed in advanced solid tumors, such as prostate, breast, colon, lung and pancreatic cancers. Differential PI3Kδ and PI3Kδ-S expression profiles were identified in a panel of solid tumor cells. PI3Kδ inhibitor Idelalisib and SRPK1 / 2 inhibitor SRPIN340 were employed to assess their efficacies on inhibiting the PI3Kδ-expressing solid tumors. Idelalisib effectively inhibits PI3Kδ-L and its downstream signaling. Idelalisib fails to inhibit PI3Kδ-S activity and its downstream signaling. SRPIN340 reverses the aberrant mRNA splicing, thereby inhibiting the downstream AKT / mTOR signaling. In vitro functional assays further demonstrate that a combination of Idelalisib and SRPIN340 achieve a synergistic drug effect, with drastically reduced cell viabilities / growths of tumor spheroids, in inhibiting the advanced tumor cells.

The application relates to the fields of biotechnology and targeted therapy, and particularly relates to a recombinant construct, a CAR-T cell and construction and application thereof. The application verifies the role and mechanism of THEMIS in maintaining the long-term killing of tumor cells of CAR-T through experiments. The CAR-T cell overexpressing THEMIS is constructed, compared with a control group, the proliferation capacity and memory cell formation capacity of the THEMIS-7x19 CAR-T cell are enhanced after antigen stimulation, and the cytokines are in a controllable state, the cell apoptosis and exhaustion are reduced, and the long-term tumor killing capacity can be maintained more effectively. The in-vivo experiment also proves that the THEMIS-7x19 CAR-T cell has stronger anti-tumor effect compared with the control group in a lymphoma tumor-bearing mouse model, and the survival time of the mouse is significantly prolonged.

A method to develop one or more morphometric classifiers to identify a mismatch repair deficiency (MMRD). The method provides a non-invasive method of characterizing MMRD that is responsive to a tumor in its early stages of development and irrespective of the tumor size. The method allows targeting cancer therapy to the specific characteristics of the cancer that the patient may have, allowing more efficient cancer management with far fewer side effects.

This invention relates to the application of SNORD15A from urinary sediment as a biomarker for early tumors, belonging to the biomedical field. The biomarker is selected from urinary sediment SNORD15A; the kit includes a reverse transcription reaction system, a quantitative real-time PCR reaction system, and an internal control system. Studies have found that SNORD15A is significantly upregulated in renal cell carcinoma patients, especially those with early-stage renal cell carcinoma, in TCGA databases, paraffin-embedded samples (FFPE), and urinary sediment compared to the control group, and the difference is statistically significant. Furthermore, SNORD15A is stable in urinary sediment and is not easily degraded by enzymes, making it a potential biomarker for the diagnosis and early diagnosis of renal cell carcinoma. Receiver operating characteristic (ROC) curves show that SNORD15A has a diagnostic efficacy (AUC) of 0.7432 for renal cell carcinoma, a sensitivity of 61.8%, and a specificity of 79%; and a diagnostic efficacy (AUC) of 0.7441 for early-stage renal cell carcinoma, with a sensitivity of 54.2% and a specificity of 87.7%, confirming the potential of SNORD15A as a novel non-invasive biomarker for the diagnosis and early diagnosis of renal cell carcinoma.

According to the technical scheme, the AI auxiliary urinary detection equipment has the advantages that primary urinary diagnosis is carried out by the aid of historical case information and sweat metabolite signals, and the primary urinary diagnosis can be carried out under the condition that abnormity exists; a deep detection branch and a dynamic weight distribution branch are used for comprehensively processing and judging multi-modal information such as a first time sequence electrochemical signal, a second time sequence electrochemical signal, current information, metabolic waste marker information, inflammation and infection indexes and the like, so that the detection effect can be improved, and the detection accuracy is ensured; computing resources can be saved; furthermore, according to the technical scheme disclosed by the invention, during deep detection, basic feature extraction is carried out by utilizing a time sequence electrochemical signal, data such as current generated by a target object in a detection process is also utilized, and dynamic weight configuration is carried out based on a preliminary detection result, so that the accuracy of early tumor screening is effectively improved through the processing, and the accuracy of early tumor screening is improved. And the false positive / false negative probability is reduced.

To provide a method with sensitivity and / or specificity to detect a tumor at an early stage.SOLUTION: Cell-free DNA molecules in a mixture of a biological sample can be analyzed to detect viral DNA. Methylation of viral DNA molecules at one or more sites in the viral genome can be determined. Mixture methylation level (s) can be measured based on one or more amounts of the plurality of cell-free DNA molecules methylated at a set of site (s) of the particular viral genome. The mixture methylation level (s) can be determined in various ways, e.g., as a density of cell-free DNA molecules that are methylated at a site or across multiple sites or regions. The mixture methylation level (s) can be compared to reference methylation level (s), e.g., determined from at least two cohorts of other subjects. The cohorts can have different classifications (including the first condition) associated with the particular viral genome. A first classification of whether the subject has the first condition can be determined based on the comparing.SELECTED DRAWING: None

The invention discloses a nano particle for enriching plasma low-abundance protein, a preparation method thereof and application related to cancer early screening, and the nano particle comprises a superparamagnetic nano core, a cationic polymer modified on the surface of the core and a targeting ligand grafted on the polymer by using a specific strategy. According to the nanoparticles, an efficient surface modification strategy is adopted, on one hand, broad-spectrum adsorption of plasma low-abundance protein is achieved through a cationic polymer, on the other hand, high-density and activity-maintained grafting of an antibody on the surface of the polymer is achieved through a 2-imino sulfane hydrochloride modification technology, the phenomenon that the antibody is inactivated due to adsorption is effectively avoided, and the stability of the nanoparticles is improved. And meanwhile, specific adsorption of tumor markers can be realized, so that a nano enrichment system with broad spectrum and specificity is really constructed. The technology provided by the invention can significantly improve the detection rate and accuracy of early tumors through liquid biopsy, and has important clinical significance.

The invention relates to an evolutionary nanorobot design method based on biological information feedback, and belongs to the crossing field of soft robots, biomedical engineering and evolutionary computation. The objective of the invention is to solve the problem that an early-stage tiny tumor cannot be automatically recognized and targeted due to the fact that a nano robot is complex in structure / function coupling, depends on tumor prior information and is difficult to dynamically adapt to a biological environment. A multi-objective evolutionary algorithm AFPO is adopted to optimize the structure behavior of the nano-robot, and minimization of parameters such as motion performance is taken as a target; generating a network CPPN coding genotype by using a composite mode, mapping the three-dimensional coordinates to material distribution, and generating a regular structure; a robust filter is designed, and individuals with stable performance are screened through Gaussian noise disturbance; constructing a filter to screen the design conforming to the manufacturing constraint; establishing a reaction flow-dilute substance coupling model based on the tumor microenvironment to generate a three-dimensional time-varying biological gradient field BGF; in the VoxCAD environment, the BGF is used for dynamically guiding the movement adjustment of the nano-robot, so that the autonomous targeting of the early tumor is realized.

The application provides a kind of nanobody, nucleotide molecule, expression plasmid, host cell, and its preparation method and purpose, belong to the field of nanobody.The nanobody has high affinity with B7-H3 protein, significantly reduces the immunological risk brought by heterogeneity, is more conducive to penetrating blood brain barrier, is easier to reach inside tumor to play therapeutic effect, and has wide application prospect in the preparation of drugs for preventing and / or treating advanced tumor.

The invention relates to an AI-assisted bladder cancer diagnosis method, device and equipment based on urine multi-omics data and a medium, and the method comprises the following steps: carrying out standardization processing on input urine genome, metabolome and proteome data, and generating a sample component distribution matrix after eliminating dimensional difference; key features are extracted through principal component analysis, and core biomarkers are screened in combination with a random forest algorithm; fusing metadata such as patient age and smoking history and core features by using a graph neural network, and constructing an individual pathological state model; and generating a risk probability and a confidence score based on a preset bladder cancer feature template. According to the method, the problems that in the prior art, multi-omics data preprocessing precision is insufficient, single omics analysis limitation is large, and clinical metadata integration and biomarker synergistic effect path mining are lacked are solved, diagnosis threshold values are dynamically adapted to individual characteristics, and the early tumor detection rate and the high-risk group screening applicability are effectively improved.

This invention relates to the field of artificial intelligence technology and discloses a personalized treatment method for cancer patients that integrates artificial intelligence. The method includes: acquiring two adjacent phases of contrast-enhanced tumor images; generating a spatially weighted oligoprogression margin after registration and lesion segmentation; constructing a graph structure containing one image node and three treatment text nodes corresponding to continuing the original systemic therapy, adding local therapy, and changing systemic therapy, respectively; and writing the margin into directed edges from the image node to each treatment node. Based on the margin, a gating mapping is performed to generate directional weights, which are combined with the initial representation of the image node to form edge messages; attention coefficients of each directed edge are calculated and normalized using attention-temperature mapping. The representations of the three treatment text nodes are updated by weighting the corresponding edge messages with the attention coefficients, outputting the probability distribution of each node. Supervised training is performed using historical treatment text labels, and shape alignment constraints are used to ensure that the gating mapping and the margin change in the same direction, resulting in a target graph neural network.

The conjugation of luteinizing hormone-releasing hormone analogs (LHRHa) to highly potent payloads via spacers (linear or branched) and cleavable peptidic linkers generate peptide drug conjugates (PDCs) with stable triazole, thioether, oxime or amide bonds. The PDCs target tumor cells that express LHRH receptor (LHRH-R) and release their payloads inside the lysosomes. The PDCs may be used in a method for killing or inhibiting the growth of a tumor cell, especially in late state, highly invasive and aggressive stage IV tumors and in reoccurring tumors.

This invention discloses a tumor adjuvant nutritional preparation based on *Pterocarya stenoptera* oil, its preparation method, and its application. The active ingredients of this preparation are composed of *Pterocarya stenoptera* oil, ω-3 fatty acids, and arginine in a mass ratio of (1-3):(1-2):(1-2), preferably 2:1:1. The preparation method includes mixing the above components evenly, followed by high-pressure homogenization and aseptic emulsification to produce an oral liquid, enteral nutrition emulsion, or powder. This preparation can effectively improve chemotherapy-induced bone marrow suppression, significantly increase white blood cell, red blood cell, and hemoglobin levels, enhance serum superoxide dismutase activity, reduce oxidative stress damage, and significantly alleviate gastrointestinal adverse reactions such as nausea, vomiting, and loss of appetite in cancer patients undergoing radiotherapy and chemotherapy, improving patients' nutritional status and quality of life, and exhibiting good safety.

The invention discloses a serum fibroblast activation protein detection kit based on latex microspheres, a detection method and application, and belongs to the technical field of biological reagents for diagnosis. The core breakthrough of the invention lies in that a dual-specificity system of latex microsphere specific adsorption and FAP targeted immunofluorescence coupling is constructed, and efficient and stable capture of the exosome is realized by virtue of the high specific surface area of the aldehyde group / sulfate latex microspheres and the specific interaction of the aldehyde group-amino group; and a high-affinity rabbit monoclonal anti-FAP antibody and a streptavidin-PE signal amplification system are matched, so that the detection problem of low-abundance FAP + Exo in an early tumor sample is successfully solved. Meanwhile, the integrity of the exosome structure and the FAP native conformation is guaranteed through the mild reaction conditions in the whole process, background interference is effectively deducted through a triple control system, and the accuracy and repeatability of the detection result are guaranteed.

This invention belongs to the field of reactive oxygen species (ROS) detection technology, and discloses a composite near-infrared ratiometric fluorescent probe, its synthesis method, and its application. The probe is composed of a cyanine organic fluorescent dye and bovine serum albumin (BSA). By using urea to disrupt the hydrogen bonds, the BSA protein molecule structure is relaxed and denatured, leading to the extension of the protein's peptide chains. These chains then bind to the synthesized organic compound Hcy-Cl to form the probe Hcy-BSA structure. The ROS level in vivo is detected by ratiometric fluorescence intensity changes. ‑ This invention designs a novel composite near-infrared ratiometric fluorescent probe, which achieves the regulation of ClO through changes in ratiometric fluorescence intensity. ‑ The detection method has advantages such as good selectivity, high stability, good biocompatibility and low toxicity, and is expected to become a powerful auxiliary reagent for the early diagnosis of tumors and Alzheimer's disease.